Synapse

← Meletios Α. Dimopoulos

Papers by Meletios Α. Dimopoulos

Page 2 · newest first

  1. Upfront Anti-CD38 Monoclonal Antibody-Based Quadruplet Therapy for Multiple Myeloma: A Systematic Review and Meta-Analysis of Clinical TrialsCancers · 2025
  2. Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA StudyJournal of Clinical Oncology · 2025
  3. Characteristics and Survival Outcomes of Solitary Plasmacytomas: A 30‐Year Experience of the Greek Myeloma Study Group on 175 PatientsAmerican Journal of Hematology · 2025
  4. Semiquantitative Analysis in PET/CT Imaging of Prostate CancerJournal of Clinical Medicine · 2025
  5. Subcutaneous daratumumab (Dara) + bortezomib/lenalidomide/dexamethasone (VRd) with Dara + lenalidomide (DR) maintenance in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM): Analysis of sustained minimal residual disease negativity in the phase 3 PERSEUS trial.Journal of Clinical Oncology · 2025
  6. Observation or treatment for smoldering multiple myeloma? A systematic review and meta-analysis of randomized controlled studiesBlood Cancer Journal · 2025
  7. Genomic landscape of multiple myeloma and its precursor conditionsNature Genetics · 2025
  8. Immunotherapy in primary hormone-receptor positive breast cancer: A systematic reviewCritical Reviews in Oncology/Hematology · 2025
  9. Cystatin C as Biomarker for the Evaluation of Renal Outcome in AL AmyloidosisAmerican Journal of Hematology · 2025
  10. Monoclonal gammopathy of undetermined significance in patients with solid tumours: Effects of immune checkpoint inhibitors on the monoclonal proteinBritish Journal of Haematology · 2025
  11. EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myelomaFuture Oncology · 2025
  12. A prospective study of small fiber neuropathy in AL amyloidosisAmyloid · 2025
  13. The Role of the Bone Marrow Microenvironment in Physical Function and Quality of Life in Patients with Multiple Myeloma After First-Line Treatment with Novel Agents and Autologous TransplantationSHILAP Revista de lepidopterología · 2025
  14. Predictive value of free light chain burden in patients with AL amyloidosis treated with bortezomib-based regimensBlood Advances · 2025
  15. A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myelomaBlood · 2025
  16. Molecular Prognostic Factors in Uterine Serous Carcinomas: A Systematic ReviewCurrent Oncology · 2025
  17. Daratumumab for newly diagnosed multiple myeloma: Pooled analysis of patients aged ≥65 years from GRIFFIN and PERSEUSClinical Lymphoma Myeloma & Leukemia · 2025
  18. Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group StudyBlood Cancer Journal · 2025
  19. Efficacy and safety of isatuximab monotherapy to treat relapsed or refractory multiple myeloma: a pooled analysis of clinical trialsAnnals of Hematology · 2025
  20. Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitorsSeminars in Hematology · 2025
  21. Modeling MRD Changes in Myeloma to Understand Treatment Effects, Predict Outcomes, and Investigate Curative PotentialClinical Cancer Research · 2025
  22. Yearly Assessment of Bone Disease in Patients with Asymptomatic Multiple Myeloma Identifies Early Progression Events and Should Be the Standard Clinical PracticeJournal of Clinical Medicine · 2025
  23. Cold pressor test and paradoxical blood pressure reduction in AL amyloidosis2025
  24. Refining precision prognostics in multiple myeloma: loss of miR-221/222 cluster in CD138+ plasma cells results in short-term progression and worse treatment outcomeBlood Cancer Journal · 2025
  25. Outcomes of Newly Diagnosed Multiple Myeloma Patients Requiring DialysisClinical Lymphoma Myeloma & Leukemia · 2025
  26. Single-cell RNA sequencing defines distinct disease subtypes and reveals hypo-responsiveness to interferon in asymptomatic Waldenstrom’s MacroglobulinemiaNature Communications · 2025
  27. The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug developmentBlood Cancer Journal · 2025
  28. Possible Prognostic Role of BMI Before Chemotherapy in the Outcomes of Women with Ovarian CancerNutrients · 2025
  29. Effects of Exercise Training on the Bone Marrow Immune Microenvironment and Minimal Residual Disease in Multiple Myeloma Patients Following First‐Line TreatmentScandinavian Journal of Medicine and Science in Sports · 2025
  30. Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta‐Analysis of Randomized Controlled TrialsAmerican Journal of Hematology · 2025
  31. Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM TrialEuropean Journal Of Haematology · 2025
  32. Precision medicine in gynecological cancer (Review)Biomedical Reports · 2025
  33. Disease Characteristics and Treatment Outcomes of Myeloma Patients Under 50 Years of Age: An Analysis of the Balkan Myeloma Study GroupClinical Lymphoma Myeloma & Leukemia · 2025
  34. Integrated Network-Based Analysis of Diseases Associated with Amyloid Deposition Through a Disease–Protein–Drug NetworkPharmaceuticals · 2024
  35. Increased serum B‐cell maturation antigen levels evaluated with an Elecsys‐based serum B‐cell maturation antigen assay have a negative prognostic value in patients with newly diagnosed multiple myelomaeJHaem · 2024
  36. Real-world evidence of Trastuzumab Deruxtecan (T-DXd) Efficacy in HER2-expressing gynecological malignanciesBMC Cancer · 2024
  37. Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemiaBlood Advances · 2024
  38. Sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort StudyBlood · 2024
  39. Efficacy and Safety of Daratumumab Monotherapy in Newly Diagnosed Patients with Stage 3B Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma NetworkBlood · 2024
  40. Trabecular Bone Score as a Complementary Tool for the Assessment of Bone Mineral Density in Patients with Asymptomatic Monoclonal GammopathiesJournal of Clinical Medicine · 2024
  41. Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myelomaLeukemia & lymphoma/Leukemia and lymphoma · 2024
  42. Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World ExperienceJournal of Hematology · 2024
  43. Dr. Raymond Alexanian: Pioneering Contributions to Multiple Myeloma Research, Treatment, and the Concept of CurabilityClinical Lymphoma Myeloma & Leukemia · 2024
  44. A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myelomaFuture Oncology · 2024
  45. Validation of the second revision of the international staging system (R2-ISS) for overall survival in multiple myeloma in a real-world cohort: an analysis by the Balkan myeloma study group (BMSG)Leukemia & lymphoma/Leukemia and lymphoma · 2024
  46. Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain AmyloidosisJAMA Oncology · 2024
  47. Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trialFuture Oncology · 2024
  48. Implications of the Hippo Pathway Dysregulation in Uterine LeiomyosarcomaAnticancer Research · 2024
  49. A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myelomaBlood Advances · 2024
  50. An open‐label, first‐in‐human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myelomaEuropean Journal Of Haematology · 2024